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recommendations, yet tuned to the national context and the 
economic specificities of the country. 
The first work-packages of the HERO project have 
objectivized a large variation within European countries in 
resource availability and in actual needs for radiotherapy 
provision, related to the national cancer incidence. It also 
showed a remarkable lack of guidance for radiotherapy 
planning, with national recommendations mostly duplicating 
the available recommendations from international 
organizations or projects, without any attempt to streamline 
them to the needs of the individual country. 
Due to the growing awareness of resource limitations and 
tightening budgets, the weighing of costs and outcomes as 
performed in economic evaluations have become an integral 
part of the health resource allocation processes in many 
countries. Whereas cost-effectiveness data are typically 
required prior to the introduction of new drugs, they 
gradually also become more frequently requested to support 
radiotherapy financing. In order to make valid 
recommendations, the economic evaluations should however 
mimic the actual clinical and economic situation of the 
specific country. Yet, cost-effectiveness data from one 
country are not necessarily representative for another. 
The next step within the HERO-project is to develop a costing 
model that provides accurate radiotherapy resource cost 
data, based on the available resources, the cancer 
epidemiology and the radiotherapy practice of individual 
European countries. Time-driven activity-based costing, a 
cost-accounting method specifically developed to capture 
product complexity and variability, is highly suitable for that 
purpose. A final step will be to evaluate how these cost data 
can be combined with effectiveness data – derived from 
international studies but applicable to a country-specific 
environment – in an adaptable economic evaluation model, 
relevant for individual countries in the heterogeneous 
European context. 
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Purpose/Objective: Despite significant improvement in 
locoregional control in the contemporary era of 
nasopharyngeal carcinoma (NPC) management, patients still 
suffer from a significant risk of distant metastasis (DM). 
Identifying those patients at risk of DM would aid in 
personalized treatment in the future. MicroRNAs (miRNAs) 
play many important roles in human cancers; hence, we 
proceeded to address the primary hypothesis that there is a 
miRNA expression signature capable of predicting DM for NPC 
patients. 
Materials and Methods: The expression of 734 miRNAs was 
measured in 125 (Training Set) and 121 (Validation Set) 
clinically annotated NPC diagnostic biopsy samples. 
Results: A 4-miRNA expression signature associated with risk 
of DM was generated by fitting a penalized Cox Proportion 
Hazard regression model to the Training data set (HR 8.25; 
p<0.001). This signature was subsequently tested in the 
Validation set, and maintained a significant relationship with 
DM (HR 3.2; p=0.01). In addition, multivariate analysis 
determined that this 4-miRNA signature was the strongest 
independent predictor when clinical factors were included. 
Finally, pathway enrichment analysis indicated that targets 
of the miRNAs comprising the final signature appear to be 
converging on cell cycle regulation. 
Conclusions: This 4-miRNA signature adds to the prognostic 
value of the current 'gold standard' of TNM staging. In-depth 
interrogation of these 4-miRNAs will provide important 
biological insights that could facilitate the discovery and 
development of novel molecularly targeted therapies to 
improve outcome for future NPC patients. 
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Purpose/Objective: Lysosome-associated membrane protein 
(LAMP)-3 is regulated by the unfolded protein response 
pathway. Our preclinical data suggest that LAMP3 plays an 
important role in autophagy induction during the response of 
breast cancer cells to various treatments and stress factors. 
We have shown that radiation therapy (RT), tamoxifen and 
hypoxia can induce LAMP3 and that high expression of LAMP3 
is associated with resistance to RT and tamoxifen in breast 
cancer cells. Moreover, patients with high levels of LAMP3 
mRNA had more locoregional recurrences. Here, we 
investigate the occurrence and clinical associations of a 
frequent non-synonymous single nucleotide polymorphism 
(SNP) in the LAMP3 gene (rs482912, Ile318Val) in 626 breast 
cancer patients. 
Materials and Methods: A custom TaqManÒ SNP Genotyping 
Assay targeted to our SNP of interest (rs482912) was used to 
assess its occurrence in breast cancer patients. We analysed 
the SNP's association with several clinical factors by Pearson 
Chi-square tests, and performed Kaplan-Meier survival and 
Cox regression analyses to investigate a relation with 
locoregional control. 
Results: In our cohort, the minor allele frequency for the 
LAMP3 rs482912SNP was 0.718, which is similar to the 
frequency in the European population. The SNP was not 
associated with menopausal status, type of operation, use of 
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RT, histological grade, tumour size or nodal stage. However, 
patients carrying the LAMP3 rs482912 SNP either 
homozygously (n=323) or heterozygously (n=253) had fewer 
locoregional recurrences than those carrying the reference 
allele (n=50, Hazard Ratio (HR) = 0.389, 95% Confidence 
Interval (CI) = 0.196-0.771, P = .007) (figure). This prognostic 
value was limited to patients treated with breast-conserving 
therapy including RT (HR = 0.265, CI = 0.104-0.674, P = .005), 
which is in line with a role for LAMP3 in radiosensitivity. 
Furthermore, the LAMP3 SNP was only prognostic in grade III 
tumours (HR = 0.270, P = .005), tumours larger than 2 cm (HR 
= 0.357, P = .011), and in patients with involved lymph nodes 
(HR = 0.154, P < .001). 
 
Figure: Breast cancer patients that carry the LAMP3 rs482912 
SNP allele (C) either homozygously or heterozygously have 
better locoregional control (P = .007). 
Conclusions: The LAMP3 rs482912 SNP is associated with 
locoregional control in a cohort of 626 breast cancer 
patients. This is specifically the case after RT as part of 
breast conserving treatment and for patients with more 
advanced or aggressive tumours.  
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Purpose/Objective: The incidence of relapse of locally 
advanced lung cancer after treatment with radio(chemo) 
therapy is still high. The significance of biologic markers such 
as heat shock protein (HSPB1) for predicting recurrence has 
been increasingly emphasized by recent investigations. We 
investigated prospectively the association between single 
nucleotide polymorphisms (SNPs) in the HSPB1 gene and the 
risk of relapse in patients with lung cancer. 
Materials and Methods: The data set consist of 156 lung 
cancer patients with available genomic DNA samples and 
treated with radio(chemo)therapy from January 2013 to 
September 2014. Median age was 63 years-old (range, 37-89) 
and the Karnofsky performance status was ≥70 except for 6 
cases. The most common histology for non-small cell lung 
cancer patients (79%) was squamous cell carcinoma (65%). 
Seventythree percent of patients had Stage III disease, 92.3% 
received platinum-based chemotherapy, and received doses 
between 39 Gy and 70 Gy (median, 63 Gy). We genotyped 
three SNPs of the HSPB1 gene (rs2868370, rs2868371, and 
rs7459185) by the TaqMan assays. Cox proportional hazards 
analysis was performed to calculate the hazard ratio (HR) and 
confidence interval (CI) of each genotype on relapse risk. 
Multivariate analyses were performed using a logistic 
regression model, with a stepwise backward elimination 
procedure. A P value of 0.05 or less was considered 
statistically significant. 
Results: The distribution of the HSPB1 genotype was: 
rs2868370, 65% GG, 32% AG, 3% AA; rs2868371, 77% CC, 18% 
CG, 5% GG; rs7459185, 51% GG, 39% CG, 10% GG).The 
incidence of relapse was 31% (24% locoregional and distant, 
18% only locoregional, and 58% only distant). In univariate 
analysis, CG/GG genotypes of HSPB1 rs2868371 were 
associated with a statistically significantly lower risk of any 
relapse (HR = 0.47; 95% CI, 0.23 to 0.97; p = 0.042) and 
distant recurrence (HR = 0.40; 95% CI, 0.17-0.93; p = 0.033) 
compared with the CC genotype. In addition, AG/AA 
genotypes of HSPB1 rs2868370 were associated with a 
statistically significantly higher risk of distant relapse (HR = 
2.19; 95% CI, 1.11 to 4.35; p = 0.024) compared with the GG 
genotype. In multivariate analysis, only the rs2868370 SNP 
retained significance (HR = 2.47; p = 0.010). 
Conclusions: Our results showed that the AG/GG genotypes 
of HSPB1 rs2868370 gene were associated with a higher risk 
of distant relapse in patients with lung cancer treated with 
radio(chemo)therapy and thus may serve as a reliable 
predictor of recurrence. This response marker may be used 
for guiding therapy intensity or as a selection criteria for a 
clinical trial in an individual patient, which would further the 
goal of individualized therapy.  
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Purpose/Objective: In a former study (1), the hypoxia gene 
expression classifier, developed in head and neck squamous 
cell carcinomas, was applied in 89 patients with loco-regional 
gastroesophageal cancer (GC). Analysis of the 15 genes was 
indicative of hypoxia being more profound in esophagus 
squamous cell carcinomas (ESCC) compared with 
adenocarcinomas of the esophago-gastric junction and the 
stomach (AC), and was a potential prognostic marker in 
patients with ESCC. The purpose of the present study was to 
confirm these results. 
Materials and Methods: The study population consisted of 
152 patients with GC treated with neoadjuvant or definitive 
chemoradiotherapy or perioperative chemotherapy. Based on 
formalin-fixed, paraffin-embedded, diagnostic biopsies, gene 
expression of the 15 hypoxia-induced and pH-independent 
genes was obtained with qPCR. Sufficient amounts of RNA for 
gene analyses were available in 135 patients; ESCC: 89 
